UKI-1


CAS No. : 220355-63-5

(Synonyms: WX-UK1; UKI-1C)

220355-63-5
Price and Availability of CAS No. : 220355-63-5
Size Price Stock
1mg $180 In-stock
5mg $420 In-stock
10mg $600 In-stock
50mg $1800 In-stock
100mg $2520 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-100415
M.Wt: 613.81
Formula: C32H47N5O5S
Purity: >98 %
Solubility: DMSO : 100 mg/mL (162.92 mM; Need ultrasonic)
Introduction of 220355-63-5 :

UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells[1][2]. IC50 & Target:Ki: 0.41 μM (Urokinase-type plasminogen activator (uPA))[2]
Serine protease[1] In Vitro: UKI-1 (WX-UK1; 0.1-1.0 μg/mL) treatment shows a decrease of tumor cell invasion by up to 50% is achieved in both models with the SCCHN line FaDu and the cervical carcinoma line HeLa[1].
UKI-1 (WX-UK1) interferes with the plasminogen activation system at 2 levels: it inhibits plasmin formation directly and via inhibition of uPA. In vitro invasion models with highly invasive fibrosarcoma and breast cancer cells showed that UKI-1 effectively inhibits migration of the cells through fibrin matrices[1]. In Vivo: UKI-1 (WX-UK1) treatment has antimetastatic activities that significantly reduces the number of metastatic lesions and tumor growth in metastasizing rat pancreatic and mammary adenocarcinoma tumor models[1].

Your information is safe with us.